TherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Friday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TherapeuticsMD stock opened at $1.86 on Friday. TherapeuticsMD has a fifty-two week low of $1.86 and a fifty-two week high of $4.73. The stock has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $2.33.

Institutional Trading of TherapeuticsMD

Institutional investors and hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in TherapeuticsMD by 6.3% in the 1st quarter. Principal Financial Group Inc. now owns 123,319 shares of the company’s stock valued at $47,000 after acquiring an additional 7,263 shares during the period. JPMorgan Chase & Co. increased its position in TherapeuticsMD by 22.6% in the 1st quarter. JPMorgan Chase & Co. now owns 255,249 shares of the company’s stock valued at $97,000 after acquiring an additional 46,974 shares during the period. State Street Corp increased its position in TherapeuticsMD by 13.6% in the 1st quarter. State Street Corp now owns 30,130 shares of the company’s stock valued at $113,000 after acquiring an additional 3,600 shares during the period. Rhumbline Advisers increased its position in TherapeuticsMD by 4.8% in the 1st quarter. Rhumbline Advisers now owns 312,526 shares of the company’s stock valued at $119,000 after acquiring an additional 14,372 shares during the period. Finally, UBS Group AG increased its position in TherapeuticsMD by 258.1% in the 2nd quarter. UBS Group AG now owns 18,133 shares of the company’s stock valued at $180,000 after acquiring an additional 13,069 shares during the period. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.